Son-Mi Park

Title: The Innovative Contributions of Son-Mi Park

Introduction

Son-Mi Park is a notable inventor based in Wuppertal, Germany. He has made significant contributions to the field of blood coagulation, particularly in the prevention and treatment of thromboembolic disorders. His innovative approach has the potential to improve patient outcomes in this critical area of healthcare.

Latest Patents

Son-Mi Park holds a patent for a method of treating thromboembolic disorders. This invention involves administering a direct factor Xa inhibitor in oral dosage form to patients in need. The method is designed for once-daily administration, utilizing a factor Xa inhibitor with a plasma concentration half-life indicative of a bid or tid administration interval, specifically 10 hours or less. This patent represents a significant advancement in the treatment of blood coagulation issues.

Career Highlights

Son-Mi Park is associated with Bayer Intellectual Property GmbH, where he continues to work on innovative solutions in the medical field. His expertise in blood coagulation has positioned him as a valuable asset to the company and the broader scientific community.

Collaborations

Son-Mi Park collaborates with esteemed colleagues, including Frank Misselwitz and Dagmar Kubitza. Their combined efforts contribute to the advancement of research and development in the field of thromboembolic disorder treatments.

Conclusion

Son-Mi Park's contributions to the field of blood coagulation through his innovative patent demonstrate his commitment to improving healthcare solutions. His work at Bayer Intellectual Property GmbH and collaborations with other experts highlight the importance of teamwork in driving medical advancements.